Ingevity price to free cash flow NGVT

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: 15.5×
10-year median: 16.5×
Against its 10-year history: 43rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.3× to 65.9×
Peer median: 26.7×

Ingevity's price to free cash flow is 15.5× as of Oct 23, 2026.

That is below its ten-year median of 16.5×, close to the middle of its last ten years.

Over that time it ranged from 7.3× in Nov 2025 to 65.9× in Nov 2024.

The median for 10 chemicals stocks of a similar size is 26.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.5×	8.2×	17.3×
2025	9.0×	7.3×	64.0×
2024	55.1×	11.5×	65.9×
2023	13.3×	10.7×	21.2×
2022	16.4×	9.1×	18.5×
2021	10.3×	10.3×	15.7×
2020	15.7×	7.3×	22.3×
2019	22.9×	22.9×	35.0×
2018	25.7×	22.3×	34.1×
2017	22.6×	22.6×	37.4×

Against its peers

Companies in Chemicals nearest Ingevity's size, closest first, today.

Company	Price to free cash flow
NGVTIngevity	15.5×
IOSPInnospec	34.7×
ROGRogers	27.0×
FULFuller H B	26.7×
WDFCWD 40	35.9×
AVNTAvient	19.7×
CBTCabot	13.6×
CRONCronos	24.8×
CSWCSW Industrials	33.4×
BCPCBalchem	n/m
HXLHexcel	23.6×
Peer median	26.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Ingevity

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.